Jun. 13, 2025 at 2:03 PM ET6 min read

PHAT Stock Surges: What Investors Need to Know

Tim BohenAvatar
Written by Tim Bohen Reviewed by Ben Sturgill Fact-checked by Ellis Hobbs

Phathom Pharmaceuticals Inc.’s stocks have been trading up by 12.36% following FDA approval of vital new treatments.

Recent Developments

  • Shares of Phathom Pharmaceuticals have skyrocketed by 96% after the U.S. FDA announced an exclusive 10-year market protection for their novel Voquezna tablets designed to reduce acid issues.

  • Following this announcement, PHAT’s shares experienced a remarkable upturn, doubling in value after the FDA approved a petition granting New Chemical Entity (NCE) exclusivity for Voquezna.

  • The FDA’s decision to award a 10-year NCE exclusivity has caused the company’s stock prices to soar by nearly 104%, firmly establishing them on the investor’s radar.

  • Consequently, PHAT’s shares almost doubled as the company’s innovative drug Voquezna gains traction with the 10-year exclusivity granted by the FDA.

Candlestick Chart

Live Update At 14:03:08 EST: On Friday, June 13, 2025 Phathom Pharmaceuticals Inc. stock [NASDAQ: PHAT] is trending up by 12.36%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Financial Snapshot of Phathom Pharmaceuticals

“Time and experience have taught me that missed opportunities are part of the game. There’s always another setup around the corner.” These words particularly resonate in the world of trading. Trades that slipped through your fingers might feel like huge losses at the moment, but the market always presents another opportunity. As Tim Bohen, lead trainer with StocksToTrade, wisely points out, one missed trade shouldn’t be a cause for despair. Embracing this mindset can help traders stay focused, calm, and ready for the next potential success.

In the recent financial report, Phathom Pharmaceuticals showcased various intriguing aspects. The revenue stood at approximately $55.3 million, which, although promising, comes with an important caveat: the expenses were significantly higher, with a total of $107M, demonstrating the company’s ongoing investments in research and operations. These figures hint at the intensive costs that companies like PHAT must endure while advancing groundbreaking treatments.

A key financial metric reflected the company’s efforts: a negative gross margin of 86.2%, underscoring the high costs in comparison to revenue. The result is a profit margin that also remains in the negative territory. Yet, with a high current ratio of 3.6, PHAT exhibits a solid capacity to cover its short-term liabilities, offering some assurance in its financial strategy.

More Breaking News

On the balance sheet side, Phathom’s total assets were over $294M, with current liabilities totaling $74M, leaving a challenging negative equity position. These figures reinforce the hurdles faced by developing pharmaceutical companies but also echo the groundwork laid for future market gains.

Deeper Insights into the Market Reaction

The robust response from the market following the FDA’s announcement is a testament to the significance of Voquezna. The stock price, which once sat at just under $5, saw a meteoric rise, peaking at over $11 in a single bound. This catalyzed momentum is indicative of investor confidence in the exclusivity and anticipated future sales of Voquezna.

Investors see this 10-year exclusivity as a beacon of potential revenue streams, reducing competitive pressures and allowing Phathom Pharmaceuticals to cement its place in the market without immediate threats from generics. This exclusivity, a rarity, offers a strategic advantage, granting them the opportunity to reap returns on their investments in research and development.

Potential Impact and Market Speculation

The heart of investors beating in sync with Phathom Pharmaceuticals’ upswing in fortunes is grounded on the FDA granting unequivocal protection for Voquezna. Historically, such protections can bestow a company with a prolonged runway to profitably capitalize on market opportunities. In this instance, as Voquezna holds its 10-year exclusivity, the market anticipates the drug to recoup development costs while potentially boosting the company’s financials considerably.

As blockbuster potential unfolds, the anticipation is heavy that Voquezna will effectively capture a significant market share. Analysts speculate PHAT’s financial posture might strengthen as sales ramp up, despite the initial setbacks. And, though the current negative financial metrics reveal ongoing expenditures, the controlled exclusivity diminishes competitive risk, providing a competitive edge poised to stimulate long-term shareholder value.

Concluding Thoughts

In conclusion, the market narrative encapsulated by Phathom Pharmaceuticals’ latest surge reflects a potent cocktail of innovation, regulatory triumph, and strategic exclusivity. Traders, emboldened by the unwavering faith in Voquezna’s potential, await a landscape ripe with opportunities. While the path to financial triumph is dotted with challenges, the luminescent glow of FDA’s 10-year protection serves as a guiding star for PHAT’s voyage. As Tim Bohen, lead trainer with StocksToTrade says, “If you’re still guessing at the end of your analysis, it’s probably not a trade worth taking.” As the dust settles, only time will tell if the bullish hopes of today will translate into the tangible gains of tomorrow.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.